Construction and Effect Evaluation of Integrated Care Model for Pulmonary Infection in Stroke Patients With Tracheotomy
1 other identifier
interventional
80
1 country
1
Brief Summary
- 1.To understand the occurrence of pulmonary infection in stroke patients with tracheotomy, and to clarify the current situation of clinical nursing.
- 2.Construct a standardized, systematic and scientific integrated care model to control the severity of pulmonary infection in non-acute stroke patients with simple tracheotomy.
- 3.To evaluate the clinical application effect of integrated care model of pulmonary infection in stroke patients with tracheotomy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable stroke
Started May 2022
Longer than P75 for not_applicable stroke
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 7, 2022
CompletedFirst Submitted
Initial submission to the registry
May 14, 2022
CompletedFirst Posted
Study publicly available on registry
August 17, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 7, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 7, 2026
CompletedAugust 17, 2022
May 1, 2022
4 years
May 14, 2022
August 15, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
Clinical Pulmonary Infection Score
The scale mainly includes 7 indicators of body temperature, white blood cell count, tracheal secretions, oxygenation, chest X-ray, progress of pulmonary exudation, and microbial culture of tracheal aspirates, each with 0 to 2 points, with a total score of 12 If the score is less than 6, the lung infection is considered to be controlled.
Within 1 week of admission
Clinical Pulmonary Infection Score
The scale mainly includes 7 indicators of body temperature, white blood cell count, tracheal secretions, oxygenation, chest X-ray, progress of pulmonary exudation, and microbial culture of tracheal aspirates, each with 0 to 2 points, with a total score of 12 If the score is less than 6, the lung infection is considered to be controlled.
3 weeks after admission
Secondary Outcomes (6)
Beck Oral Assessment Score(BOAS),modified
Within 1 week of admission
Beck Oral Assessment Score(BOAS),modified
3 weeks after admission
Zarit Caregiver Burden Interview, ZBI
Within 1 week of admission
Zarit Caregiver Burden Interview, ZBI
3 weeks after admission
EuroQol-5 Dimension, EQ-5D
Within 1 week of admission
- +1 more secondary outcomes
Other Outcomes (1)
hospital costs
≥3 weeks
Study Arms (2)
control group
NO INTERVENTIONImplement routine nursing such as: routine oral nursing, tracheostomy, dressing change, sputum suction nursing, oral education, etc.
intervention group
EXPERIMENTALImplement comprehensive nursing models such as: admission risk assessment, personalized oral care based on beck oral score, aspiration prevention, airway care, diversified health education
Interventions
The interventions in this study were to implement basic patient care only and did not involve any invasive procedures. On the basis of routine nursing, the content of nursing intervention was integrated, and a standardized nursing model was formed for clinical application to control the severity of pulmonary infection in patients with simple tracheotomy in the non-acute phase of stroke.
Eligibility Criteria
You may qualify if:
- Non-acute stroke patients diagnosed by MRI or CT who meet the diagnostic criteria of the "Chinese Guidelines for the Prevention and Treatment of Cerebrovascular Diseases";
- Those who meet the diagnostic criteria for pulmonary infection;
- Age ≥18 years old;
- Tracheotomy patients who have been off the ventilator or do not need mechanical ventilation;
- Patients who can cooperate with the research and sign the informed consent.
You may not qualify if:
- Patients whose vital signs are unstable and may be transferred to ICU for treatment in the future;
- Patients with malignant tumors or other infectious diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Second People's Hospital of Shenzhen
Shenzhen, Guangdong, 518035, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yan Gao, Ph.D
Shenzhen Second People's Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 14, 2022
First Posted
August 17, 2022
Study Start
May 7, 2022
Primary Completion
May 7, 2026
Study Completion
May 7, 2026
Last Updated
August 17, 2022
Record last verified: 2022-05
Data Sharing
- IPD Sharing
- Will not share
Contact the principal investigator for data if necessary